We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Biomarker-Based Blood Test Assesses Risk for Diabetic Kidney Disease Before Symptoms Appear

By LabMedica International staff writers
Posted on 06 Dec 2022
Print article
Image: NaviDKD is the first and only scientifically-proven predictive screening for diabetic kidney disease (Photo courtesy of Journey Biosciences)
Image: NaviDKD is the first and only scientifically-proven predictive screening for diabetic kidney disease (Photo courtesy of Journey Biosciences)

Diabetic kidney disease (DKD) is a serious health condition that often goes undetected until irreparable damage has been done to the kidneys and kidney function. One-in-three adults with diabetes will develop kidney disease. And, in 90% of cases, they won’t know they have it until it has advanced to the point where they need dialysis or a kidney transplant to survive, as it develops slowly and without symptoms. Now, the first and only scientifically-based screening technology provides an early read on the risk of developing kidney disease for people with diabetes, giving them and their doctors time to take preventative action and improve outcomes.

Journey Biosciences, Inc. (Lebanon, NH, USA) has launched NaviDKD, a biomarker-based blood test that proactively assesses the risk of kidney disease in people with diabetes years before clinical signs or symptoms appear. Along with its proprietary Compass reporting platform, NaviDKD provides actionable insights for preventing and managing kidney complications before they occur. NaviDKD is the first and only scientifically-proven predictive screening for DKD and provides healthcare providers with the insights needed to preserve their patients' kidney health, avoid complications, and improve outcomes.

By proactively assessing risk 10+ years in advance of clinical signs and symptoms, NaviDKD provides the opportunity to treat with therapeutics and technologies to change the outcome. By combining the simplicity of a blood test with the advanced science of predictive biomarkers, NaviDKD gives healthcare providers and their patients an early alert of their individual risk - giving a decade or more to make informed decisions that preserve their kidney health.

"For the one-in-three people with diabetes who will develop diabetic kidney disease, NaviDKD provides an opportunity to fundamentally change their ultimate health outcomes," said Adam Graybill, Chief Executive Officer of Journey Biosciences. "By identifying those at elevated or high risk of developing DKD before any symptoms or clinical indications, the conversation between doctor and patient can focus on taking proactive, preventative action instead of reacting to an unwanted diagnosis."

Related Links:
Journey Biosciences, Inc.

Platinum Supplier
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Gold Supplier
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Supplier
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE

Print article


Molecular Diagnostics

view channel
Image: Newly identified biomarkers may detect early cognitive decline via a blood test (Photo courtesy of 123RF)

Blood Tests to Enable Early Identification of Cognitive Decline and Personalized Treatments

Some individuals who have endured extreme stressors like psychiatric disorders or childhood abuse and neglect can experience a variety of health issues later in life, such as depression, anxiety, and cardiovascular... Read more


view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more


view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more


view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more


view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more


view channel
Image: Made-to-order diagnostic tests may soon be on the horizon (Photo courtesy of McGill University)

Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible

Home testing gained significant importance during the COVID-19 pandemic, yet the availability of rapid tests is limited, and most of them can only drive one liquid across the strip, leading to continued... Read more


view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.